Open Access<p>Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer</p>
Author(s) -
Zhaoqin Zhu,
Lanlan Ling,
Lezhong Qi,
Yue Chong,
Li Xue
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s245848
Subject(s) - bruton's tyrosine kinase , du145 , prostate cancer , ibrutinib , cancer research , cancer , medicine , metastasis , cancer cell , tyrosine kinase , cell growth , chemistry , leukemia , chronic lymphocytic leukemia , receptor , biochemistry , lncap
Bruton's tyrosine kinase (BTK) inhibitors have long been known in the treatment of B-cell malignancies. Recently, BTK inhibitors have also become promising novel treatment reagents for prostate cancer. The current study was designed to investigate expression of BTK in prostate cancer tissues in comparison with benign hyperplasia and effect of BTK inhibitor on prostate cancer cell proliferation, migration and invasion.